Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07863466
Recruiting Observational

MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms

NCT07863466 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase
Observational
Started
2025-02-17
Last updated
2026-10-07

Condition(s) studied

Myelofibrosis (MF)Polycythemia VeraEssential Thrombocythaemia

Study summary

Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation into secondary acute myeloid leukemia. MPNs include: myelofibrosis, polycythemia vera, and essential thrombocythemia. The low incidence, comparable to that of rare diseases, induces the in-depth study of patients and thus the need to develop a project with databases to collect clinical, biological, and therapeutic information.

Eligibility

Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients 16 years of age and older * Patients diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis (Arber et al, Blood 2022 or earlier but reclassified classifications) Exclusion Criteria: * Patients with diagnosis other than polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis * Follow up of less than 6 months

Primary outcome measure(s)

  • Overall Survival — 20 years

Trial sites (1)

FacilityCityRegionStatus
Ospedale Maggiore Policlinico Milan Italy Recruiting

More Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico trials in Italy

Effectiveness of Cognitive Stimulation Treatment in Patients With Parkinson's Disease Recruiting
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD) Recruiting
TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models Recruiting
Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes Recruiting
Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome Analysis Recruiting

Other trials for the same condition

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera Recruiting
Study to Assess SLN124 in Patients With Polycythemia Vera Active, not recruiting
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes Recruiting
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) Recruiting
ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07863466 on ClinicalTrials.gov ↗ ← All trials in Italy